MAPK1 and colorectal carcinoma: Moreover, butyrate has been shown to inhibit several oncogenic signaling pathways, such as mitogen-activated protein kinase 1 (MAPK1) and small mothers against decapentaplegic homolog 3 (SMAD3), that are closely associated with the pathogenesis and progression of CRC by regulating cellular proliferation and apoptosis (153).